Islamabad, Sep 9: Lucky Core Industries Limited (PSX: LCI) has notified the main bourse on Monday that it has successfully acquired a manufacturing facility situated at B2 SITE Karachi that is held by Pfizer Pakistan Limited. Additionally, LCI has acquired various pharmaceutical items.
According to the stock filing, the asset acquisition was finished on September 06, 2024, in compliance with the Asset Purchase Agreements signed by the parties.
The following pharmaceutical goods have been registered:(1) Ansaid;(2) Ponstan;(3) Ponstan Forte;(4) Basoquin;(5) Deltacortril;(6) Lysovit;(7) Corex-D; and (8) Mycitracin; moreover, trademarks related to these pharmaceutical products from pertinent Pfizer group businesses are included.
LCI’s share price on the market was Rs. 1,019.99 at the time of filing, up 0.49 percent or Rs. 5 on Monday’s turnover of 22,708 shares.
